PCSK9 and Combined hyperlipidemia: We therefore evaluated the effect of PCSK9-inhibition on lipoprotein subfractions in patients with FDBL and compared it to the effect in patients with LDL-hypercholesterolemia and patients with mixed hyperlipidemia (not FDBL).